The Valley Desk

NCT04649359 · Interventional trial

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Overall registry status Completed

Phase 2

Conditions Multiple Myeloma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov